新华制药
(000756)
| 流通市值：60.81亿 | | | 总市值：84.93亿 |
| 流通股本：4.99亿 | | | 总股本：6.97亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,060,829,901.78 | 4,357,548,611.17 | 2,423,049,619.1 | 8,754,721,987.78 |
| 营业收入 | 6,060,829,901.78 | 4,357,548,611.17 | 2,423,049,619.1 | 8,754,721,987.78 |
| 二、营业总成本 | 5,824,222,054.24 | 4,159,524,749.7 | 2,313,460,629.83 | 8,390,212,699.23 |
| 营业成本 | 4,927,789,293.5 | 3,522,514,897.69 | 1,981,945,053.94 | 7,110,179,626.73 |
| 税金及附加 | 54,883,572.36 | 39,139,782.42 | 22,865,468.49 | 65,098,579.77 |
| 销售费用 | 220,229,370.05 | 167,749,175.94 | 103,476,027.03 | 341,082,001.85 |
| 管理费用 | 307,373,037.15 | 206,930,932.69 | 94,907,605.7 | 457,662,218.64 |
| 研发费用 | 269,640,747.46 | 192,694,792.28 | 95,473,864.96 | 381,617,425.73 |
| 财务费用 | 44,306,033.72 | 30,495,168.68 | 14,792,609.71 | 34,572,846.51 |
| 其中:利息费用 | 25,231,958.69 | 17,264,463.43 | 8,449,572.07 | 42,431,327.39 |
| 其中:利息收入 | 3,961,955.19 | 2,621,550.54 | 1,165,719.39 | 7,685,444.95 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 7,238,588.61 | 7,363,123.47 | 333,529.89 | 7,764,521.27 |
| 资产处置收益 | 152,746.21 | 93,383.69 | 108,900.17 | 1,990,589.09 |
| 资产减值损失(新) | -40,425,032.15 | -40,425,032.15 | - | -47,394,139.35 |
| 信用减值损失(新) | -6,187,277.52 | -6,248,825.3 | 50,250 | -5,351,752.99 |
| 其他收益 | 26,899,967.98 | 16,853,626.8 | 8,951,288.61 | 42,466,344.69 |
| 四、营业利润 | 224,286,840.67 | 175,660,137.98 | 119,032,957.94 | 363,984,851.26 |
| 加:营业外收入 | 2,282,702.96 | 1,789,050.85 | 676,607.62 | 5,415,769.48 |
| 减:营业外支出 | 13,385,944.7 | 12,506,676.44 | 1,076,787.65 | 10,484,117.56 |
| 五、利润总额 | 213,183,598.93 | 164,942,512.39 | 118,632,777.91 | 358,916,503.18 |
| 减:所得税费用 | 19,328,539.09 | 16,987,719.37 | 35,365,534.05 | 52,612,585.03 |
| 六、净利润 | 193,855,059.84 | 147,954,793.02 | 83,267,243.86 | 306,303,918.15 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 193,855,059.84 | 147,954,793.02 | 83,267,243.86 | 306,303,918.15 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 195,042,988.98 | 149,127,526.81 | 83,903,044.36 | 289,888,855 |
| 少数股东损益 | -1,187,929.14 | -1,172,733.79 | -635,800.5 | 16,415,063.15 |
| 扣除非经常损益后的净利润 | 186,892,626.52 | 147,309,628.75 | 80,291,736.33 | 268,343,425.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.28 | 0.21 | 0.12 | 0.42 |
| (二)稀释每股收益 | 0.28 | 0.21 | 0.12 | 0.42 |
| 八、其他综合收益 | -46,702,764.91 | -65,971,211.38 | -23,698,036.77 | 26,020,010.31 |
| 归属于母公司股东的其他综合收益 | -46,034,253.4 | -65,449,015.5 | -23,434,398.84 | 26,360,028.52 |
| 九、综合收益总额 | 147,152,294.93 | 81,983,581.64 | 59,569,207.09 | 332,323,928.46 |
| 归属于母公司股东的综合收益总额 | 149,008,735.58 | 83,678,511.31 | 60,468,645.52 | 316,248,883.52 |
| 归属于少数股东的综合收益总额 | -1,856,440.65 | -1,694,929.67 | -899,438.43 | 16,075,044.94 |
| 公告日期 | 2026-10-29 | 2026-08-26 | 2026-04-29 | 2026-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |